Senseonics Holdings Inc
AMEX:SENS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Senseonics Holdings Inc
AMEX:SENS
|
US |
|
American Woodmark Corp
NASDAQ:AMWD
|
US |
|
Neo-Concept International Group Holdings Ltd
NASDAQ:NCI
|
HK |
|
Hindustan Hardy Ltd
BSE:505893
|
IN |
Senseonics Holdings Inc
Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. The company is headquartered in Germantown, Maryland and currently employs 121 full-time employees. The company went IPO on 2015-03-04. The firm is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. The company is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.
Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. The company is headquartered in Germantown, Maryland and currently employs 121 full-time employees. The company went IPO on 2015-03-04. The firm is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. The company is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.
Revenue: Full-year 2025 revenue was $35.3 million, up from $22.5 million in 2024; Q4 revenue was $14.3 million.
Growth Drivers: Senseonics brought commercialization in-house, doubled U.S. patient count year-over-year and grew new patient starts 103% in 2025, driven by DTC marketing and provider adoption.
Margins: Gross profit in Q4 was $7.7 million and full-year margins improved to greater than 50% by year end; company expects full-year 2026 gross profit margin to be greater than 50%.
2026 Guidance: Net revenue is expected to be approximately $58 million to $62 million, with operating expenses of $150 million to $160 million and cash use of $110 million to $120 million.
Commercial Execution: U.S. sales transition from Ascensia was executed smoothly with nearly 100% of reps moving to Senseonics; European CE mark received and planned launches in Germany, Italy, Spain and Sweden.
Product Pipeline: Gemini pivotal completion expected by end of 2026 with launch in 2027; Freedom planned for 2028. Integration with Sequel twiist AID pump is live.
Balance Sheet: Cash, restricted cash and equivalents totaled $94.3 million as of December 31, 2025, and debt and accrued interest were $35.3 million.
